RedHill Biopharma Provides Update on Opaganib (Yeliva®)       Phase 2 study evaluating RedHill’s proprietary NCE1 opaganib (Yeliva®, ABC294640) in prostate cancer initiated at Medical University of South Carolina, supported by an NCI grant --- ...

RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma The first stage of the Phase IIa study with YELIVA® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can...

RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential of YELIVA™ in Cholangiocarcinoma Cancer The article was authored by scientists from the Mayo Clinic Cancer Center, the Hollings Cancer Center at the Medical University of South Carolina and Apogee Biotechnology Corporation  RedHill...